Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells

Since many oncogenes, including BCR-ABL, may promote the acquisition and maintenance of the glycolytic phenotype, we tested whether treatment of BCR-ABL-driven human leukemia cells with imatinib, a selective BCR-ABL inhibitor, can modulate the expression of key glycolytic enzymes and mitochondrial c...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int J Mol Sci
Päätekijät: De Rosa, Viviana, Monti, Marcello, Terlizzi, Cristina, Fonti, Rosa, Del Vecchio, Silvana, Iommelli, Francesca
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2019
Aiheet:
Communication
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6651622/
https://ncbi.nlm.nih.gov/pubmed/31252559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20133134
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia